{
  "id": 20717070,
  "title": "AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets",
  "url": "https://urgent.news/2026/11/19/abbvie-and-disco-strike-deal-worth-up-to-2-54b-for-solid-tumor-targets",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T07:00:40.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/abbvvie-and-disco-strike-deal-worth-more-than-2-5b-for-solid-tumor-targets/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AbbVie is partnering with Disco Pharmaceuticals, a preclinical cancer biotech, to build out its antibody-drug conjugate and T cell engager programs. The Cologne, Germany-headquartered biotech will receive $40 million upfront and up to $2.5 billion ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma",
        "url": "https://urgent.news/2026/11/19/abbvie-inks-up-to-2-54b-bispecific-cancer-drug-deal-with-disco-pharma",
        "published": "2026-11-19T07:30:30.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}